Kuan C J, Wells J N, Jackson E K
Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232.
Circ Res. 1990 Mar;66(3):637-46. doi: 10.1161/01.res.66.3.637.
The purpose of this study was to test the hypothesis that endogenous adenosine functions to restrain the renin release response to pharmacological and pathophysiological stimuli. To achieve this objective, we examined the effects of an adenosine receptor antagonist, 1,3-dipropyl-8-(p-sulfophenyl)xanthine (DPSPX), on the renin release response induced by acute administration of hydralazine or by chronic clipping of the left renal artery (renovascular hypertensive rats). In conscious, unrestrained rats, DPSPX significantly increased plasma renin activity (PRA) in control rats, in rats treated with hydralazine, and in renovascular hypertensive rats. The effect of DPSPX on PRA was significantly greater in rats treated with hydralazine or in renovascular hypertensive rats compared with control rats. DPSPX did not influence arterial blood pressure in any group, did not affect the measurement of PRA, and did not alter the elimination of renin activity from the circulation. Additional experiments were performed in the in situ autoperfused kidney so that the effects of DPSPX on renal hemodynamics and renal excretory function could be assessed. In this experimental model, DPSPX also increased PRA in hydralazine-treated rats and in renovascular hypertensive rats without affecting arterial pressure, renal blood flow, or sodium excretion. In a final set of studies in conscious, unrestrained rats, adenosine deaminase increased PRA in a dose-dependent manner in hydralazine-treated rats and significantly increased the slope of the relation between PRA and the depressor response to hydralazine. We conclude: 1) Although the kidney has both A1 and A2 adenosine receptors mediating inhibitory and stimulatory actions, respectively, on renin release, the dominant effect of endogenous adenosine on renin release is inhibitory. 2) Even under basal physiological conditions, endogenous adenosine tonically inhibits renin release. 3) This inhibitory effect is augmented whenever the renin-angiotensin system is stimulated regardless of the approach used to activate renin release. 4) Endogenous adenosine negatively modulates renin release by a direct effect on juxtaglomerular cells.
本研究的目的是验证内源性腺苷具有抑制肾素释放对药理学和病理生理学刺激反应的假说。为实现这一目标,我们研究了腺苷受体拮抗剂1,3 - 二丙基 - 8 -(对 - 磺苯基)黄嘌呤(DPSPX)对急性给予肼屈嗪或慢性夹闭左肾动脉(肾血管性高血压大鼠)诱导的肾素释放反应的影响。在清醒、未束缚的大鼠中,DPSPX显著增加了对照大鼠、接受肼屈嗪治疗的大鼠以及肾血管性高血压大鼠的血浆肾素活性(PRA)。与对照大鼠相比,DPSPX对接受肼屈嗪治疗的大鼠或肾血管性高血压大鼠的PRA的影响显著更大。DPSPX在任何组中均不影响动脉血压,不影响PRA的测量,也不改变肾素活性从循环中的清除。在原位自体灌注肾中进行了额外的实验,以便评估DPSPX对肾血流动力学和肾排泄功能的影响。在该实验模型中,DPSPX在接受肼屈嗪治疗的大鼠和肾血管性高血压大鼠中也增加了PRA,而不影响动脉血压、肾血流量或钠排泄。在清醒、未束缚大鼠的最后一组研究中,腺苷脱氨酶在接受肼屈嗪治疗的大鼠中以剂量依赖性方式增加PRA,并显著增加PRA与肼屈嗪降压反应之间关系的斜率。我们得出以下结论:1)尽管肾脏具有A1和A2腺苷受体,分别介导对肾素释放的抑制和刺激作用,但内源性腺苷对肾素释放的主要作用是抑制性的。2)即使在基础生理条件下,内源性腺苷也持续抑制肾素释放。3)无论用于激活肾素释放的方法如何,只要肾素 - 血管紧张素系统受到刺激,这种抑制作用就会增强。4)内源性腺苷通过对球旁细胞的直接作用对肾素释放进行负性调节。